

ASX Announcement

Dr John Le Gall appointed Chief Medical Officer

- Dr John Le Gall MD MBA appointed Chief Medical Officer, effective immediately
- Dr Le Gall was previously Vice President, Head of Clinical Development at Allogene Therapeutics, and brings clinical development leadership experience in allogeneic CD19 CAR T
- Dr John Byon to step down as Chief Medical Officer by mutual agreement and will continue to support the Company as a consultant
- No interruption to the azer-cel clinical program is anticipated

SYDNEY, Australia, 7 October 2026: Imugene Limited (ASX: IMU) (“Imugene” or “the Company”) announces the appointment of Dr John Le Gall MD MBA as Chief Medical Officer, effective immediately. Dr John Byon will step down as Chief Medical Officer by mutual agreement.

The change follows the Company’s decision to concentrate its resources on azer-cel, its allogeneic CD19 CAR T cell therapy. As a single-asset company, the Board has restructured the Chief Medical Officer role to match the Company’s current scale of clinical activity and cost base.

Dr Byon will continue to support the Company as a consultant to ensure continuity for investigators and patients. Day-to-day medical monitoring of the azer-cel trial continues through the company’s in-house clinical team and CRO (contract research organisation). The Company does not anticipate any interruption to the azer-cel clinical program.

Dr Le Gall is a physician-scientist with clinical development leadership experience in CAR T and other cell therapies. Most recently he was Vice President, Head of Clinical Development at Allogene Therapeutics (2023–2026), where he led clinical development across early and late-stage programs, including redesigning and implementing the



pivotal development plan for cema-cel, an allogeneic CD19 CAR T cell therapy.

Before Allogene, Dr Le Gall was Vice President, Clinical Development at Instil Bio, where he led clinical development, operations, biometrics and safety. Earlier he was Director, Clinical Development at Kite, a Gilead Company, where he led the AML and myeloma program teams and was medical monitor on studies of Yescarta® (axicabtagene ciloleucel).

Dr Le Gall trained in paediatric haematology and oncology at Johns Hopkins University and the US National Cancer Institute. He holds an MD and MBA from Columbia University and is board-certified in paediatric haematology-oncology.

Dr Byon joined Imugene in 2023 and has led the azer-cel clinical program through Phase 1b. The Board thanks Dr Byon for his contribution and the foundation he has built for the program.

Imugene Executive Chairman Paul Hopper said: “It has been a pleasure to work with John and for the Company to be the beneficiary of his deep cell-therapy knowledge and experience and his contribution to the azer-cel programme.

Imugene is now a focused, single-asset company, and our cost base must reflect that. John Byon’s work has brought azer-cel to where it is today, and we are grateful he will continue to support the program through the transition. In John Le Gall we have secured deep allogeneic CD19 CAR T experience in a structure that fits the company we now are. Our focus remains on ongoing clinical execution from the Phase 1b azer-cel clinical trial, upcoming data readouts, and future regulatory interactions.”

Dr Byon said: “It has been a privilege to lead the azer-cel clinical program, including the results we reported this week. I leave confident in where the program is heading and, in the team taking it forward, and I will work closely with John to ensure a seamless handover for our investigators and patients.”

Dr Le Gall said: “The emerging clinical profile for azer-cel, including the latest Phase 1b results, demonstrates a clear rationale for an allogeneic, off-the-shelf CD19 CAR T in



patients with B-cell cancers that have progressed on current treatments. I look forward to working with the team and our investigators on the next stage of development.”

About the Phase 1b azer-cel trial

The ongoing, open-label Phase 1b trial of azer-cel in the U.S. and Australia evaluates three main patient populations: CAR T-relapsed patients, CAR T-naïve patients, and a concurrent BTKi cohort of patients with B-cell malignancies who previously failed BTKi therapy. Across a broad range of non-Hodgkin lymphomas (including FL, CLL/SLL, MZL, WM, and MCL), treatment with azer-cel, lymphodepletion, and IL-2 has yielded meaningful clinical activity including multiple complete responses in the BTKi cohort, with a manageable safety and tolerability profile.

For more information please contact:

General Investor Enquiries

shareholderenquiries@imugene.com

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.

Release authorised by the Executive Chairman, Imugene Limited.